Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-13 4:21 pm Sale | 13G | KINNATE BIOPHARMA INC KNTE | Vida Ventures LLC | 2,207,772 5% | -539,661 (-19.64%) | View |
| 2023-02-03 4:27 pm Purchase | 13G | KINNATE BIOPHARMA INC KNTE | BlackRock Inc. BLK | 2,335,818 5.3% | 2,335,818 (New Position) | View |
| 2023-01-23 4:28 pm Purchase | 13G | KINNATE BIOPHARMA INC KNTE | Lynx1 Capital Management LP | 2,213,178 5% | 2,213,178 (New Position) | View |
| 2022-02-14 4:11 pm Unchanged | 13G | KINNATE BIOPHARMA INC KNTE | RA CAPITAL MANAGEMENT L.P. | 3,593,052 8.2% | 0 (Unchanged) | View |
| 2022-02-10 5:17 pm Purchase | 13G | KINNATE BIOPHARMA INC KNTE | Vida Ventures LLC | 2,747,433 6.3% | 359 (+0.01%) | View |
| 2022-02-09 09:22 am Sale | 13G | KINNATE BIOPHARMA INC KNTE | FMR LLC | 2,092,523 4.788% | -357,612 (-14.60%) | View |
| 2021-02-16 4:39 pm Purchase | 13G | KINNATE BIOPHARMA INC KNTE | RA CAPITAL MANAGEMENT L.P. | 3,593,052 8.3% | 3,593,052 (New Position) | View |
| 2021-02-16 4:00 pm Purchase | 13G | KINNATE BIOPHARMA INC KNTE | Nextech V Oncology S.C.S. SICAV-SIF | 3,008,243 6.9% | 3,008,243 (New Position) | View |
| 2021-02-12 5:40 pm Purchase | 13G | KINNATE BIOPHARMA INC KNTE | Vida Ventures LLC | 2,747,074 6.3% | 2,747,074 (New Position) | View |
| 2021-02-08 10:25 am Purchase | 13G | KINNATE BIOPHARMA INC KNTE | FMR LLC | 2,450,135 5.654% | 2,450,135 (New Position) | View |
| 2020-12-14 9:24 pm Purchase | 13D | KINNATE BIOPHARMA INC KNTE | Foresite Capital Fund IV L.P. | 10,838,311 25% | 10,838,311 (New Position) | View |
| 2020-12-11 4:39 pm Purchase | 13D | KINNATE BIOPHARMA INC KNTE | ORBIMED ADVISORS LLC | 3,397,929 7.8% | 3,397,929 (New Position) | View |